The non-profit BioUK has announced its acquisition of certain key assets of SEHTA (Science and Engineering Health Technologies Alliance) through an asset purchase agreement.
The two organisations have complementary areas of expertise, with BioUK primarily supporting biotech and therapeutics companies and SEHTA supporting MedTech and HealthTech firms.
By bringing SEHTA's assets into BioUK, the organisation can now support a much broader range of life sciences businesses.
BioUK will also gain access to SEHTA's established network of more than 1200 members, potentially creating more opportunities for collaboration, partnerships and investment.
It will also benefit from SEHTA's experience helping businesses understand how to get their products adopted by healthcare providers, including the NHS.
Neil Roberts (SEHTA’s Managing Director) and Clare Ansett (Operations Manager) will join BioUK’s transition team to support SEHTA members who would benefit from transferring to BioUK membership and to support relationships with the previous SEHTA expert associate network.
The SEHTA brand will be wholly absorbed and will operate under the BioUK brand.
Stuart Rose, CEO of BioUK, said: “The integration of some of SEHTA’s key assets is an important strategic move for BioUK and we’re delighted to welcome its members to the BioUK community."
Bringing those assets under the BioUK brand is an opportunity to expand beyond our biotech and therapeutics roots, widening our SME ecosystem and, through incorporating SEHTA’s expertise, allowing us to better fulfil our mission to catalyse success across the entire life science sector.
Neil Roberts, MD of SEHTA, said: “For twenty years, SEHTA has helped MedTech and HealthTech SMEs successfully navigate the path from concept to commercialisation and I'm proud of the community we've built."
This asset transfer to BioUK is a real step forward for our members. They gain access to a broader nationwide network, industry-leading events, more investor connections and significant savings through BioUK's purchasing consortium, while the market access and grant-funding expertise they value carries on.
"Our MedTech and HealthTech knowledge will now be included to make BioUK the prominent membership organisation within the life science sector."
The acquisition also reflects a broader effort to bring different parts of the UK life sciences ecosystem together.
